Hexarelin belongs to the growth hormone releasing peptide family, working through the ghrelin receptor to prompt growth hormone release. It attracted some research interest because of possible direct effects on heart tissue, separate from the growth hormone pathway, which distinguished it from its relatives. That line of investigation never produced an approved medicine and no substantial modern development programme survives. Like the other compounds in this group it does what it says on the hormone panel and has never been shown to deliver the physical outcomes people pursue it for. Its evidence base is a scattering of small early studies from decades ago, and it is now essentially a research chemical with a footnote in cardiology literature.